Our Pricing

Mounjaro vs Saxenda: Clinical Comparison for UK Patients

When considering mounjaro vs saxenda uk comparison options, understanding the clinical differences between tirzepatide and liraglutide is essential for making an informed treatment choice. Both are MHRA-licensed injectable medications for weight management, but they work through different mechanisms and produce distinct clinical outcomes. At Cured Pharmacy, our UK-registered clinical team provides evidence-based guidance to help you choose the most suitable treatment, with transparent pricing from £135.00 for Saxenda and from £135.00 for Mounjaro.

How Mounjaro and Saxenda Work Differently

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed in the UK for weight management [1]. This dual-action mechanism activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, producing enhanced effects on appetite regulation, insulin secretion, and energy expenditure compared to single-pathway treatments.

Saxenda contains liraglutide, a GLP-1 receptor agonist that has been available in the UK since 2015 [2]. It works by mimicking a single natural hormone that regulates appetite and food intake, slowing gastric emptying and increasing feelings of fullness after meals. While effective, its single-pathway mechanism produces more modest weight loss outcomes compared to dual-receptor agonists.

The fundamental difference in mechanism translates directly to clinical efficacy. In head-to-head comparisons, dual-action treatments consistently demonstrate superior weight reduction, though both medications require daily or weekly injections and ongoing clinical monitoring by UK prescribers.

Mounjaro vs Saxenda: Clinical Effectiveness Compared

In the SURPASS-3 trial, patients receiving the highest maintenance dose of Mounjaro (15mg weekly) achieved an average 22.5% total body weight reduction over 72 weeks [1]. This represents significantly greater efficacy than traditional single-pathway GLP-1 treatments, with over half of participants achieving at least 20% weight loss.

By comparison, the SCALE Obesity and Prediabetes trial showed that Saxenda users achieved an average 8.0% body weight reduction over 56 weeks, with 33.1% of participants losing at least 10% of their initial weight [2]. While clinically meaningful, these outcomes are notably lower than those observed with dual-receptor agonist therapy.

Both medications require adherence to a reduced-calorie diet and increased physical activity to achieve optimal results. Your UK prescriber will assess your medical history, current BMI, and any contraindications before determining which treatment is most appropriate for your individual circumstances.

Weight Loss Timeline Expectations

Mounjaro follows a gradual dose escalation schedule, starting at 2.5mg weekly and increasing every four weeks until reaching your maintenance dose. Most patients begin noticing appetite reduction within the first two weeks, with measurable weight loss typically evident by week 4-8 [3].

Saxenda is administered as a daily injection, starting at 0.6mg and increasing by 0.6mg increments weekly until reaching the 3.0mg maintenance dose. Weight loss typically becomes noticeable within 4-6 weeks of reaching the full dose, with maximum effects seen after several months of consistent use [2].

Dosing and Administration: Mounjaro vs Saxenda UK

Mounjaro is administered once weekly using a pre-filled KwikPen device. The standard dose escalation begins at 2.5mg weekly for four weeks, then increases to 5mg, 7.5mg, 10mg, 12.5mg, and finally 15mg at four-week intervals, depending on individual response and tolerability [1]. This weekly schedule offers greater convenience for patients who prefer less frequent injections.

Saxenda requires daily subcutaneous injections, with the pen delivering doses from 0.6mg up to the maintenance dose of 3.0mg. The daily administration schedule provides steady medication levels but requires greater commitment to a daily injection routine [2]. Each Saxenda pen contains enough medication for several days, depending on your prescribed dose.

Both medications are injected subcutaneously into the abdomen, thigh, or upper arm. Injection sites should be rotated to prevent lipodystrophy. Your UK clinical team will provide detailed administration instructions during your consultation, and all prescription orders include patient information leaflets with step-by-step guidance.

Side Effects: What UK Patients Should Expect

The most common side effects for both Mounjaro and Saxenda are gastrointestinal, including nausea, diarrhoea, vomiting, constipation, and abdominal discomfort [1][2]. These effects are typically most pronounced during dose escalation and often diminish as your body adjusts to the medication. Starting with lower doses and increasing gradually helps minimise these symptoms.

In clinical trials, approximately 44% of Mounjaro users experienced nausea, compared to 39% of Saxenda users [1][2]. However, severe gastrointestinal side effects leading to treatment discontinuation were relatively uncommon in both groups when proper dose titration protocols were followed.

Rare but serious side effects include pancreatitis, gallbladder problems, and thyroid C-cell tumours (observed in animal studies). Both medications carry a boxed warning regarding thyroid tumours and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [1][2]. Your UK prescriber will screen for these contraindications during your clinical assessment.

Managing Common Side Effects

To minimise nausea and gastrointestinal discomfort, eat smaller, more frequent meals and avoid high-fat foods, particularly during the first few weeks of treatment. Staying well-hydrated and avoiding lying down immediately after eating can also reduce symptoms. If side effects become severe or persistent, contact your prescriber to discuss dose adjustments or alternative treatment options.

Cost Comparison: Mounjaro vs Saxenda at UK Pharmacies

At Cured Pharmacy, Saxenda is available from £135.00 and Mounjaro from £135.00, with final pricing determined by your prescribed dose and treatment duration. Both medications require ongoing monthly prescriptions, and your UK prescriber will determine the most cost-effective treatment plan based on your clinical response and individual circumstances.

When comparing overall value, consider both the upfront cost and the clinical effectiveness demonstrated in trials. While Mounjaro carries a higher initial price point, its superior average weight loss outcomes and once-weekly dosing schedule may represent better long-term value for some patients. Conversely, Saxenda's lower starting price and established safety profile make it an accessible option for those beginning weight management treatment.

All prescription weight loss medications at Cured Pharmacy include a free online consultation with a UK-registered prescriber, discreet packaging, and transparent upfront pricing with no hidden fees. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), ensures all dispensed medications meet MHRA standards for quality and safety.

Choosing Between Mounjaro and Saxenda: Clinical Considerations

Your UK prescriber will assess multiple factors when recommending treatment, including your current BMI, weight loss goals, medical history, existing medications, and any contraindications. Patients with higher baseline BMI or those who have not achieved adequate results with single-pathway GLP-1 treatments may be better candidates for Mounjaro's dual-receptor mechanism [3].

Saxenda may be more appropriate for patients new to weight loss medications, those with budget constraints, or individuals who have previously responded well to GLP-1 therapy. Its longer track record in the UK market and daily dosing schedule provide flexibility for patients who prefer more frequent, lower-dose administration [2].

Both treatments require commitment to lifestyle modifications, including a reduced-calorie diet and increased physical activity, to achieve optimal results. Neither medication is suitable for patients with a personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, or severe gastrointestinal disease. Your clinical assessment will identify any contraindications before treatment begins.

Alternative Weight Loss Treatments Available

If neither Mounjaro nor Saxenda is suitable for your circumstances, Cured Pharmacy offers alternative MHRA-licensed weight management treatments including Wegovy (semaglutide) from £135.00, Orlistat from £135.00, and Xenical from £135.00. Each treatment works through different mechanisms and may be more appropriate depending on your individual clinical profile and treatment goals. Your UK prescriber will discuss all suitable options during your free online consultation.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
2. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892
3. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to a reduced-calorie diet and increased physical activity alongside medication use.